News for Y-Mabs Therapeutics Inc Stock (YMAB)

YMAB LAWSUIT: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact the Firm's Attorneys, Securities Fraud Class Action Filed

Newsfile Corp • 01/26/23

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (YMAB)

Business Wire • 01/26/23

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Y-mAbs Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile Corp • 01/26/23

Wolf Popper LLP Reminds Y-mAbs Therapeutics, Inc. Investors of Upcoming March 20, 2023 Lead Plaintiff Application Deadline

Newsfile Corp • 01/26/23

How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?

MarketBeat • 01/26/23

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (YMAB)

Business Wire • 01/25/23

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Y-mAbs Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile Corp • 01/25/23

Y-MABS THERAPEUTICS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess Of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. - YMAB

Business Wire • 01/25/23

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Y-mAbs Therapeutics, Inc. (YMAB) Investors

Business Wire • 01/24/23

NOTICE: Investors in Y-mAbs Therapeutics, Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – YMAB

Business Wire • 01/24/23

YMAB LAWSUIT ALERT: Levi & Korsinsky Notifies Y-mAbs Therapeutics, Inc. Investors Of a Class Action Lawsuit and Upcoming Deadline

Newsfile Corp • 01/23/23

YMAB INVESTOR NEWS: ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMAB

Newsfile Corp • 01/23/23

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Y-mAbs Therapeutics, Inc. (YMAB) Investors

Business Wire • 01/23/23

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact the Firm's Attorneys, Securities Fraud Class Action Pending

Newsfile Corp • 01/23/23

INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Y-mAbs Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile Corp • 01/23/23

Y-MABS THERAPEUTICS, INC. (YMAB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces That a Securities Class Action Lawsuit Has Been Filed Against Y-mAbs Therapeutics, Inc. (YMAB)

Newsfile Corp • 01/23/23

Y-MABS THERAPEUTICS, INC. (NASDAQ: YMAB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)

PRNewsWire • 01/22/23

INVESTOR DEADLINE: Y-mAbs Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - YMAB

Newsfile Corp • 01/21/23

ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMAB

PRNewsWire • 01/21/23

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Y-mAbs Therapeutics, Inc. (YMAB)

Business Wire • 01/20/23

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Y-mAbs Therapeutics, Inc. (YMAB) on Behalf of Investors

Business Wire • 01/20/23

SHAREHOLDER ACTION ALERT: Scott+Scott Attorneys at Law LLP Reminds Investors That a Securities Class Action Has Been Filed Against Y-mAbs Therapeutics, Inc. (YMAB)

Newsfile Corp • 01/20/23

Y-MABS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Y-mAbs Therapeutics, Inc. and Encourages Investors to Contact the Firm

Business Wire • 01/20/23

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Y-mAbs Therapeutics, Inc. (YMAB) on Behalf of Investors

Business Wire • 01/19/23

Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Y-mAbs Therapeutics, Inc. (YMAB) Investors

Business Wire • 01/19/23